Clinical utility of serum sclerostin measurements
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/β-catenin signaling pathway requisite for osteoblast development and activity. Efforts over the past several years have focused on unraveling the role of sclerostin in both normal physiological and pathological conditions. Sclerostin levels are undetectable in the serum of patients with sclerosteosis. In normal individuals, serum sclerostin levels are higher in males and increase in both sexes across the adult lifespan. Some, but not other, studies have demonstrated that higher serum sclerostin levels are associated with increased fracture risk, particularly when paired with lower bone mineral density. Levels of circulating sclerostin are highly correlated with bone marrow sclerostin levels. Sclerostin levels are inversely related to parathyroid hormone levels. Clinical conditions in which serum sclerostin levels have been measured include ankylosing spondylitis, chronic kidney disease, diabetes, fractures, hypercortisolism, multiple myeloma and spinal cord injury. Even within clearly defined clinical conditions, however, consistent changes in serum sclerostin levels have not always been seen. This may reflect differences in currently available commercial assays or sample sources (serum versus plasma), and suggests further study is needed before sclerostin measurements are introduced into routine clinical practice. Until such issues are resolved, measurement of sclerostin levels appears to be most useful for understanding the mechanisms by which osteocytes regulate bone turnover through the integration of hormonal, physical and pharmacological stimuli, rather than to guide clinical-care decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“Among these secreted Wnt pathway antagonists is sclerostin, identified only a decade ago as a 213 amino-acid glycoprotein whose loss of function results in the autosomal recessive bone dysplasia sclerosteosis.(2,3) Sclerostin is secreted by osteocytes, and humans with inactivating sclerostin mutations have significant…”
BackgroundBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 1×
“Among these secreted Wnt pathway antagonists is sclerostin, identified only a decade ago as a 213 amino-acid glycoprotein whose loss of function results in the autosomal recessive bone dysplasia sclerosteosis.(2,3) Sclerostin is secreted by osteocytes, and humans with inactivating sclerostin mutations have significant…”
BackgroundAmrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Cited by
Role and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
The role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 290
Self-citationShi, T., Shen, S., Shi, Y., Wang, Q., Zhang, G., Lin, J., Chen, J., Bai, F., Zhang, L., Wang, Y., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00989-x · Cited by 87
“Therefore, it is still needed to perform large-scale clinical studies to investigate whether high serum levels of sclerostin in combination with low BMD could be an independent risk factor for AD progression 51 .”
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
Self-citationEffects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing
Farr, J. N., Roforth, M. M., Fujita, K., Nicks, K. M., Cunningham, J. M., Atkinson, E. J., Therneau, T. M., McCready, L. K., Peterson, J. M., Drake, M. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138347 · Cited by 75
Self-citationSclerostin in excessive drinkers: relationships with liver function and body composition
Martín González, C., Fernández Rodríguez, C. M., Abreu González, P., García Rodríguez, A., Alvisa Negrín, J. C., Cabañas Perales, E., González Navarrete, L., Vera Delgado, V. E., Ortega Toledo, P., & González Reimers, E. (2022) · Nutrients · doi:10.3390/nu14132574 · Cited by 9
Metadata
- Authors
- Clarke, B. L., & Drake, M. T.
- Venue
- BoneKEy Reports
- Publisher
- Portico
- Published
- 2013-06-05
- Volume
- 2
- Pages
- 361-361
- ISSN
- 2047-6396 (ISSN-L)
- OpenAlex
- W2057961407
- Cited by
- 89
- References
- 3
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.